Home › malignancies
 

Keywords :   


Tag: malignancies

OHSU Hematological Malignancies & Bone Marrow Transplant

2019-01-26 02:12:38| PortlandOnline

Tags: bone transplant malignancies ohsu

 

New KEYTRUDA (pembrolizumab) Data to be Presented at 17th World Conference on Lung Cancer Highlight Research Across the Spectrum of Thoracic Malignancies

2016-11-30 13:00:00| Merck.com - Product News

Dateline City: KENILWORTH, N.J. Findings to be Presented in Non-Small Cell Lung Cancer, Small Cell Lung Cancer and Malignant Pleural Mesothelioma with KEYTRUDA as Monotherapy and in Combination with Other Treatments Quality of Life Data from KEYNOTE-024 in First-Line Non-Small Cell Lung Cancer to be Presented in Plenary Session KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that new data investigating the use of KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, across multiple thoracic malignancies, including non-small cell lung cancer (NSCLC), small cell lung cancer and malignant pleural mesothelioma, will be presented at the 17th World Conference on Lung Cancer (WCLC) hosted by the International Association for the Study of Lung Cancer in Vienna, Austria, Dec. Language: English Contact: Media Contacts:Pamela Eisele, (267) 305-3558orKim Hamilton, (908) 740-1863orInvestor Contacts:Teri Loxam, (908) 740-1986orAmy Klug, (908) 740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: the of world data

 
 

Boston Strategics Corporation Initiates A Phase 1 Clinical Trial Of The Anti-Cancer Agent FF-10501' For FUJIFILM In Patients With Advanced Hematologic Malignancies

2014-09-03 11:37:54| drugdiscoveryonline Home Page

Boston Strategics Corporation (BSC), a primary global strategic drug development provider for FUJIFILM Pharmaceuticals U.S.A., Inc. (FPHU), has begun a Phase 1 clinical trial of FUJIFILM’s anti-cancer agent FF-10501 in the United States in patients with advanced hematologic malignancies, such as relapsed or refractory high-risk myelodysplastic syndromes (MDS)

Tags: with advanced corporation agent

 

Sites : [1]